RT Journal Article
SR Electronic
T1 Reversing Immunosenescence with Senolytics to Enhance Tumor Immunotherapy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.10.14.24315428
DO 10.1101/2024.10.14.24315428
A1 Liu, Niu
A1 Wu, Jiaying
A1 Deng, Enze
A1 Zhong, Jianglong
A1 Wei, Bin
A1 Cai, Tingting
A1 Duan, Xiaohui
A1 Fu, Sha
A1 Osei-Hwedieh, David O.
A1 Sha, Ou
A1 Chen, Yunsheng
A1 Lv, Xiaobin
A1 Zhu, Yingying
A1 Zhang, Lizao
A1 Lin, Hsinyu
A1 Li, Qunxing
A1 Lu, Peichia
A1 Miao, Jiahao
A1 Yamada, Teppei
A1 Cai, Lei
A1 Du, Hongwei
A1 Baca, Sylvan C.
A1 Huang, Qingpei
A1 Ferrone, Soldano
A1 Wang, Xinhui
A1 Xu, Fang
A1 Fan, Xiaoying
A1 Fan, Song
YR 2024
UL http://medrxiv.org/content/early/2024/10/15/2024.10.14.24315428.abstract
AB Recent advancements in cancer immunotherapy have improved patient outcomes, yet responses to immunotherapy remain moderate. We conducted a Phase II clinical trial (NCT04718415) involving 51 cancer patients undergoing neoadjuvant chemoimmunotherapy and applied single-cell RNA and T/BCR sequencing on tumor and blood samples to elucidate the immune cell perturbations. Our findings associate poor response with reduced levels of CCR7+CD4 Naïve T cells and CD27+ Memory B cells, as well as higher expression of immunosenescence-related genes in T and B cell subsets. Using naturally aged and Ercc1+/- transgenic aging mouse models, we found that senolytics enhance the therapeutic efficacy of immunotherapy in multiple solid tumors by mitigating tumor immunosenescence. Notably, we launched a Phase II clinical trial, COIS-01 (NCT05724329), which pioneers the combination of senolytics with anti-PD-1 therapy. The clinical results demonstrate that this therapeutic strategy is associated with a favorable safety profile and therapeutic efficacy, significantly mitigating adverse effects and alleviating immunosenescence. These findings underscore the pivotal role of immunosenescence characteristics in influencing the effectiveness of immunotherapy and suggest a promising therapeutic efficacy along with a beneficial safety assessment for the combination of senolytics with anti-PD-1 therapy.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT05724329Funding StatementThis study was funded by the Joint Funds of the National Natural Science Foundation of China (U21A20381), the General Funds of the National Natural Science Foundation of China (82373452), the Guangdong Natural Science Funds for Distinguished Young Scholar (2022B1515020061), the Guangdong Basic and Applied Basic Research Foundation (2021A1515220138), the Guangzhou Basic Research Program Jointly Funded by Municipal Schools (Institutes) (202201020367), the Fundamental Research Funds for the Central Universities, Sun Yat-sen University (16ykpy10), the Fundamental Research Funds for the Central Universities, Sun Yat-sen University (19ykzd20), the General Funds of the National Natural Science Foundation of China (32071451), the Guangdong Provincial Pearl River Talents Program (2021QN02Y747), the Shenzhen Science and Technology Program (RCYX20210706092100003), and by the Shenzhen Medical Research Funds grant (A2303005).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee of Sun Yat-sen Memorial Hospital, Sun Yat-sen University gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.